COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma (03-15-2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm an estimated 45% of patients who received Tafinlar... Continue Reading

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (10-24-2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (10-11-2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form of a mole. If detected and treatable with surgery,... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (09-20-2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory results have led to this treatment combination... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (07-21-2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (05-25-2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (12-2-2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which Opdivo has been approved in the past 12 months. The... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (11-9-2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer, as it is more likely than other forms of skin... Continue Reading

Imlygic® Approved for Melanoma (10-28-2015)

Imlygic® (talimogene laherparepvec), the first ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma. The approval is for the treatment of melanoma sites in the skin and lymph nodes that cannot be surgically removed.... Continue Reading

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma (06-29-2015)

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology... Continue Reading

« Previous PageNext Page »